Indication
focal segmental glomerulosclerosis
13 clinical trials
13 products
1 drug
Clinical trial
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGCStatus: Recruiting, Estimated PCD: 2025-03-10
Product
R3R01Clinical trial
An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic SyndromeStatus: Terminated, Estimated PCD: 2020-06-24
Product
CCX140-BProduct
SparsentanClinical trial
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular DiseasesStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney DiseasesStatus: Completed, Estimated PCD: 2019-01-02
Product
Bardoxolone methylClinical trial
A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS)Status: Terminated, Estimated PCD: 2023-05-03
Product
VB119Clinical trial
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation StudyStatus: Completed, Estimated PCD: 2016-06-01
Product
RE-021Product
IrbesartanClinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy SubjectsStatus: Recruiting, Estimated PCD: 2024-02-16
Product
PlaceboProduct
HS-10390Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)Status: Completed, Estimated PCD: 2020-02-19
Clinical trial
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantStatus: Recruiting, Estimated PCD: 2025-08-31
Drug
VarlilumabClinical trial
Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseaseStatus: Completed, Estimated PCD: 2023-10-03
Product
adalimumabClinical trial
AMPK-activation by Metformin in FSGS: AMP-FSGSStatus: Recruiting, Estimated PCD: 2027-11-01
Product
MetforminClinical trial
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular DiseasesStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Product
AtrasentanClinical trial
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGSStatus: Active (not recruiting), Estimated PCD: 2023-03-20
Product
sparsentan